Phage display-derived oligopeptide-functionalized probes for in vivo specific photoacoustic imaging of osteosarcoma

Specific detection of various tumor types remains crucial for designing effective treatment strategies. We demonstrate photoacoustic imaging (PAI) using high-affinity and high-specificity peptide-based probes for accurate and specific diagnosis of osteosarcoma. Herein, two new tumor-specific oligopeptides, termed PT6 and PT7, were identified using phage display-based screening on an osteosarcoma cell line (UMR-106). The identified oligopeptides were able to detect clinical osteosarcoma samples on tissue microarrays. Oligopeptide-conjugated PEGylated gold nanorods (PGNR) were designed to specifically target UMR-106 cells. More importantly, PAI revealed that both PGNR-PT6 and PGNR-PT7 could bind selectively to subcutaneous UMR-106 xenografts after systemic administration and enhance the contrast of osteosarcoma images by 170% and 230%, respectively, compared to tumor-bearing mice injected with PGNRs conjugated to scrambled oligopeptides. PAI employing PGNRs conjugated to specifically designed nanoprobes may provide a new method for tumor type-specific diagnosis of osteosarcoma.

Graphical AbstractWe identified two oligopeptides (PT6 and PT7) that could specifically bind to osteosarcoma cells (UMR-106) using phage display-based screening. And the oligopeptides appeared to be selective for clinical samples recognized. Due to its high and specific binding to UMR-106, PGNR-PT6 and PGNR-PT7 nanoprobe-mediated photoacoustic imaging was proved to be an efficient modality for tumor type-specific diagnosis of osteosarcoma.173